Trial Profile
First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Ciclosporin; Ciclosporin; Methylprednisolone; Prednisolone
- Indications Haemophagocytic lymphohistiocytosis
- Focus Therapeutic Use
- 10 Dec 2019 Results of a retrospective analysis of 26 patients (pilot study) and prospective analysis of 29 enrolled patients presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 10 Dec 2019 Status changed to completed, according to the results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 20 Dec 2017 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.